These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2088344)

  • 1. Ampligen trials.
    Am Fam Physician; 1990 Oct; 42(4):1123. PubMed ID: 2088344
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute reactions associated with the infusion of ampligen.
    McMahon D; Winkelstein A; Huang XL; Armstrong J; Pazin G; Rinaldo C; Tripoli C; Ho M
    AIDS; 1992 Feb; 6(2):235-6. PubMed ID: 1558725
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic potential of Ampligen.
    Brodsky I; Strayer DR
    Am Fam Physician; 1987 Oct; 36(4):253-6. PubMed ID: 3673869
    [No Abstract]   [Full Text] [Related]  

  • 4. Trial will add immunotherapeutic agent to first cycle of antiviral cocktails.
    AIDS Read; 2001 Feb; 11(2):85. PubMed ID: 11279885
    [No Abstract]   [Full Text] [Related]  

  • 5. [Epidemiological news on infectious diseases].
    Vella S; Rocchi G
    Medicina (Firenze); 1988; 8(2):233-4. PubMed ID: 2852294
    [No Abstract]   [Full Text] [Related]  

  • 6. New "ThetaSwitch" drug may increase long-term survival in HIV disease.
    J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):59. PubMed ID: 11363523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inhibition of alfa interferon and ampligen of human immunodeficiency virus (HIV) replication in monocyte-macrophage subpopulations].
    Bergamini A; Ercoli L; Perno CF
    Medicina (Firenze); 1990; 10(1):34-6. PubMed ID: 2381279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical studies with Ampligen (mismatched double-stranded RNA).
    Carter WA; Strayer DR; Hubbell HR; Brodsky I
    J Biol Response Mod; 1985 Oct; 4(5):495-502. PubMed ID: 4078595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U), without synergistic toxicity to bone marrow progenitor cell elements.
    Gillespie D; Hubbell HR; Carter WA; Midgette P; Elsasser W; Mullaney R; Strayer DR
    In Vivo; 1994; 8(3):375-81. PubMed ID: 7803722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical studies with ampligen (mismatched double-stranded RNA).
    Brodsky I; Strayer DR; Krueger LJ; Carter WA
    J Biol Response Mod; 1985 Dec; 4(6):669-75. PubMed ID: 4087035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An hypothesis concerning optimal therapy in HIV disease.
    Gillespie D; Carter WA
    Med Hypotheses; 1992 Jan; 37(1):1-5. PubMed ID: 1569900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ampligen treatment of renal cell carcinoma: changes in 2-5A synthetase, 2-5A oligomer size and natural killer cell activity associated with antitumor response clinically.
    Suhadolnik RJ; Reichenbach NL; Lee C; Strayer DR; Brodsky I; Carter WA
    Prog Clin Biol Res; 1985; 202():449-56. PubMed ID: 3913964
    [No Abstract]   [Full Text] [Related]  

  • 13. Mismatched double-stranded RNA, Ampligen (poly(I): poly(C12U), demonstrates antiviral and immunostimulatory activities in HIV disease.
    Carter WA; Ventura D; Shapiro DE; Strayer DR; Gillespie DH; Hubbell HR
    Int J Immunopharmacol; 1991; 13 Suppl 1():69-76. PubMed ID: 1688087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antiviral activity of amantadine and poly (C,S4U) on influenza virus infection of infant rats.
    Potter CW; Teh CZ; Harvey L; Jennings R
    J Antimicrob Chemother; 1981 May; 7(5):575-84. PubMed ID: 6973566
    [No Abstract]   [Full Text] [Related]  

  • 15. Ampligen inhibits human herpesvirus-6 in vitro.
    Ablashi DV; Berneman ZN; Williams M; Strayer DR; Kramarsky B; Suhadolnik RJ; Reichenbach N; Hiltzges P; Komaroff AL
    In Vivo; 1994; 8(4):587-91. PubMed ID: 7893986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex.
    Carter WA; Strayer DR; Brodsky I; Lewin M; Pellegrino MG; Einck L; Henriques HF; Simon GL; Parenti DM; Scheib RG
    Lancet; 1987 Jun; 1(8545):1286-92. PubMed ID: 2884413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mismatched dsRNA (ampligen) induces protection against genomic variants of the human immunodeficiency virus type 1 (HIV-1) in a multiplicity of target cells.
    Montefiori DC; Robinson WE; Mitchell WM
    Antiviral Res; 1988; 9(1-2):47-55. PubMed ID: 2968777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of synthetic polyribonucleotides on EL-4 lymphoma.
    Winchurch RA; Gibson R; Godla G; Mardiney MR
    J Reticuloendothel Soc; 1975 Oct; 18(4):244-51. PubMed ID: 1202222
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative studies of ampligen (mismatched double-stranded RNA) and interferons.
    Carter WA; Hubbell HR; Krueger LJ; Strayer DR
    J Biol Response Mod; 1985 Dec; 4(6):613-20. PubMed ID: 2418160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro.
    Navabi H; Jasani B; Reece A; Clayton A; Tabi Z; Donninger C; Mason M; Adams M
    Vaccine; 2009 Jan; 27(1):107-15. PubMed ID: 18977262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.